Literature DB >> 17706178

Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

Gerald Reischl1, Donna S Dorow, Carleen Cullinane, Andrew Katsifis, Peter Roselt, David Binns, Rodney J Hicks.   

Abstract

PURPOSE: This study was performed to compare the 2-nitroimidazole derivatives [124I]IAZA, [18F]FAZA and well known [18F]FMISO in visualization of tumor hypoxia in a mouse model of human cancer using small animal PET.
METHODS: PET imaging of female Balb/c nude mice bearing A431 tumors on a Phillips Mosaic small animal PET scanner was performed 3 h p.i. for all three tracers. Mice injected with [124I]IAZA were scanned again after 24 h and 48 h. In addition to the mice breathing air, in the case of [18F]FAZA and [124I]IAZA a second group of mice for each tracer was kept in an atmosphere of carbogen gas (5% of CO2 + 95 % of O2; from 1 h before to 3 h after injection) to evaluate the oxygenation dependency on uptake (all experiments n = 4). After the final PET scan animals were sacrificed and biodistribution was studied.
RESULTS: Mice injected with [18F]FAZA displayed significantly higher tumor-to background (T/B) ratios (5.19 +/- 0.73) compared to those injected with [18F]FMISO (3.98 +/- 0.66; P $lt; 0.05) or [124I]IAZA (2.06 +/- 0.26; P $lt; 0.001) 3 h p.i. Carbogen breathing mice showed lower ratios ([18F]FAZA: 4.06 +/- 0.59; [124I]IAZA: 2.02 +/- 0.36). The T/B ratios increased for [124I]IAZA with time (24 h: 3.83 +/- 0.61; 48 h: 4.20 +/- 0.80), but after these late time points the absolute whole body activity was very low, as could be seen from the biodistribution data (< 0.1 %ID/g for each investigated organ) and ratios were still lower than for [18F]FAZA 3 h p.i. Due to de-iodination uptake in thyroid was high. Biodistribution data were in good agreement with the PET results.
CONCLUSIONS: [18F]FAZA showed superior biokinetics compared to [18F]FMISO and [124I]IAZA in this study. Imaging at later time points that are not possible with the short lived 18F labeled tracers resulted in no advantage for [124I]IAZA, i. e. tumor to normal tissue ratios could not be improved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706178

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  42 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

2.  A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Authors:  Satish K Chitneni; Gerald T Bida; Mark W Dewhirst; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-06-22       Impact factor: 2.408

3.  PET imaging with hypoxia tracers: a must in radiation therapy.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04       Impact factor: 9.236

4.  Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma.

Authors:  Takaaki Beppu; Kazunori Terasaki; Toshiaki Sasaki; Shunrou Fujiwara; Hideki Matsuura; Kuniaki Ogasawara; Koichiro Sera; Noriyuki Yamada; Noriyuki Uesugi; Tamotsu Sugai; Kohsuke Kudo; Makoto Sasaki; Shigeru Ehara; Ren Iwata; Yoshihiro Takai
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

Review 5.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 6.  An overview of the developments and potential applications of 68Ga-labelled PET/CT hypoxia imaging.

Authors:  Philippa L Bresser; Mariza Vorster; Mike M Sathekge
Journal:  Ann Nucl Med       Date:  2021-01-05       Impact factor: 2.668

Review 7.  The role of nuclear medicine in modern therapy of cancer.

Authors:  Gabriela Kramer-Marek; Jacek Capala
Journal:  Tumour Biol       Date:  2012-03-24

Review 8.  Kinetic modeling in PET imaging of hypoxia.

Authors:  Fan Li; Jesper T Joergensen; Anders E Hansen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 9.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 10.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.